Accuray (NASDAQ:ARAY) Releases Earnings Results, Beats Expectations By $0.03 EPS

Accuray (NASDAQ:ARAY - Get Free Report) issued its quarterly earnings results on Wednesday. The medical equipment provider reported $0.02 EPS for the quarter, topping analysts' consensus estimates of ($0.01) by $0.03, Zacks reports. Accuray had a negative net margin of 0.96% and a negative return on equity of 9.75%. Accuray updated its FY 2025 guidance to EPS.

Accuray Trading Down 9.7 %

ARAY traded down $0.26 during midday trading on Friday, hitting $2.43. The company's stock had a trading volume of 1,102,571 shares, compared to its average volume of 769,263. Accuray has a 52-week low of $1.40 and a 52-week high of $2.95. The firm has a 50-day moving average price of $2.11 and a two-hundred day moving average price of $1.97. The company has a current ratio of 1.62, a quick ratio of 0.87 and a debt-to-equity ratio of 3.51. The firm has a market cap of $249.88 million, a P/E ratio of -48.60 and a beta of 1.51.

Wall Street Analysts Forecast Growth

Separately, StockNews.com cut shares of Accuray from a "buy" rating to a "hold" rating in a research note on Friday, November 15th.

Accuray Company Profile

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.